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GM-CSF and IL-3 are hematopoietic cytokines that also modulate the effector functions 
of several immune cell subsets. In particular, GM-CSF and IL-3 exert a significant control 
on monocyte and macrophage effector functions, as assessed in experimental models 
of inflammatory and autoimmune diseases and also in human studies. Here, we sought 
to investigate the mechanisms and the extent to which GM-CSF and IL-3 modulate 
the pro-inflammatory, LPS-mediated, activation of human CD14+ monocytes taking into 
account the new concept of trained immunity (i.e., the priming stimulus modulates the 
response to subsequent stimuli mainly by inducing chromatin remodeling and increased 
transcription at relevant genetic loci). We demonstrate that GM-CSF and IL-3 priming 
enhances TNF-α production upon subsequent LPS stimulation (short-term model of 
trained immunity) in a p38- and SIRT2-dependent manner without increasing TNF 
primary transcript levels (a more direct measure of transcription), thus supporting a 
posttranscriptional regulation of TNF-α in primed monocytes. GM-CSF and IL-3 priming 
followed by 6  days of resting also results in increased TNF-α production upon LPS 
stimulation (long-term model of trained immunity). In this case, however, GM-CSF and 
IL-3 priming induces a c-Myc-dependent monocyte renewal and increase in cell number 
that is in turn responsible for heightened TNF-α production. Overall, our results provide 
insights to understand the biology of monocytes in health and disease conditions in 
which the hematopoietic cytokines GM-CSF and IL-3 play a role and also extend our 
knowledge of the cellular and molecular mechanisms of trained immunity.
Keywords: innate immune memory, immunometabolism, inflammation, monocyte, macrophage, Tlr, 
gM-csF, il-3
inTrODUcTiOn
GM-CSF and IL-3 are hematopoietic cytokines that bind to heterodimeric receptors composed 
of a β common subunit (CD131) and specific α subunits (CD116 and CD123, respectively) (1, 
2). These cytokines are produced by many immune and non-immune cells and are important 
mediators of emergency myelopoiesis, albeit their role in steady-state myelopoiesis is dispensable 
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(3–6). GM-CSF and IL-3 also modulate the effector functions 
of several mature immune cell subsets and have been shown to 
play a role in inflammatory and autoimmune diseases (7–11). 
For example, GM-CSF promotes the maturation and effector 
functions of myeloid cells (e.g., monocytes and neutrophils) 
and plays a protective role in an experimental model of acute 
sepsis (12). On the other hand, IL-3 exacerbates myelopoiesis 
and incites a cytokine storm (i.e., TNF-α, IL-1β, and IL-6) that 
is detrimental to the host in the same sepsis model (6). In an 
animal model of multiple sclerosis (experimental autoimmune 
encephalomyelitis), conditional deletion of Csf2rb (the mouse 
ortholog of CD131) in CCR2+ monocytes abrogates a pathoge-
netic signature that is required for disease development (7, 8). 
Interestingly, GM-CSF modulates several functions of human 
CD14+ monocytes (13–15), including cytokine production 
upon LPS stimulation. We have recently shown that GM-CSF 
and IL-3 synergize with IL-4 to enhance the production of the 
IL-4-responsive chemokine CCL17/TARC by human CD14+ 
monocytes (16). Thus, GM-CSF and IL-3 exert a significant 
control on monocyte effector functions. The mechanisms 
and the extent to which GM-CSF and IL-3 modulate the pro-
inflammatory (e.g., LPS-mediated) activation of human CD14+ 
monocytes are still unclear.
Most of the functional and molecular studies on monocyte 
and macrophage effector functions have relied on the activa-
tion of these cells by discrete stimuli. However, it is now clear 
that monocytes and macrophages are exposed to a plethora 
of stimuli in  vivo that eventually determines their functional 
specialization (17). Moreover, these cells may be exposed to dif-
ferent and sometimes opposing stimuli in a sequential manner, 
and the priming stimulus may exert a significant control over 
the response to subsequent stimuli. This phenomenon, which is 
referred to as trained immunity or innate immune memory, has 
been reported in several organisms and with a variety of stimuli, 
including toll-like receptor (TLR) agonists and cytokines (18, 
19). The in vitro and in vivo experimental approaches employed 
so far consist of either priming followed shortly after (e.g., the 
next day) by activation with the same or a different stimulus 
(short-term model) (20–25) or priming followed by prolonged 
resting (e.g., 5–6 days or several weeks) before stimulation (long-
term model) (26–30). Most of these models point to chromatin 
remodeling as a mechanism to retain memory of the priming 
stimulus. Critically, in  vivo evidence of trained immunity has 
also been obtained in humans (27). Nevertheless, we still lack 
complete knowledge of the mediators and the cellular and 
molecular mechanisms of trained immunity. The answer to these 
questions is poised to have broad implications for understanding 
the pathogenesis of and defining new therapeutic strategies for 
infectious and chronic inflammatory diseases as well as vaccine 
design (19, 31, 32).
Here, we sought to investigate whether GM-CSF and IL-3 
modulate the pro-inflammatory, LPS-mediated, activation of 
human CD14+ monocytes taking into account the new concept of 
trained immunity. We found that in a short-term model of trained 
immunity, GM-CSF and IL-3 priming enhances LPS-induced 
TNF-α production in a SIRT2- and p38-dependent manner by 
increasing TNF-α protein levels without significantly modifying 
RNA levels. At variance with this, in a long-term model of trained 
immunity, GM-CSF and IL-3 priming induces monocyte 
renewal in a c-Myc-dependent manner, thereby enhancing LPS-
induced TNF-α production. Our results uncover new mediators 
(GM-CSF and IL-3) in in vitro models of trained immunity that 
modulate TNF-α production through transcription-independent 
mechanisms.
MaTerials anD MeThODs
cell isolation and culture
The study protocol involving the use of human blood cells was 
approved by the Ethics Committee of the University of Naples 
Federico II. Cells were isolated from buffy coats of healthy donors. 
Blood was layered onto Histopaque-1077 (Sigma-Aldrich) and 
mononuclear cells were collected at the interface. Monocytes 
were further purified with anti-CD14 Microbeads (Miltenyi 
Biotec). Purity of cell preparations was >95% as assessed by flow 
cytometry. Cells were cultured in cIMDM-5 [IMDM, 5% FCS, 1× 
non-essential amino acids, 1× UltraGlutamine, 25 mM HEPES, 
5  µg/mL gentamicin (Lonza)] in 96-well flat-bottom plates 
(105  monocytes/well) in a final volume of 250  µL. For experi-
ments involving flow cytometry, cells were cultured in suspension 
(1.5 mL tubes) in cIMDM-5 at a concentration not greater than 
2 × 106 cells/mL, then spun down and collected for subsequent 
experiments.
Cells were treated with different combinations of: LPS 
(Escherichia coli 026:B6) 10 ng/mL (Sigma-Aldrich), IL-3 5 ng/
mL (Peprotech), M-CSF 25 ng/mL, GM-CSF 5 ng/mL (Miltenyi 
Biotec), P3CSK4 10 ng/mL, Poly(I:C) 1 µg/mL, flagellin 10 ng/
mL, imiquimod 1 µg/mL, ODN2006 1 µM (Invivogen), BAY11-
7082 1 µM, SP600125 2 µM, rapamycin 50 and 250 nM, torin1 10 
and 50 nM, AGK2 10 µM, APO866 0.1, 1, and 10 nM, TG101348 
125, 250, and 500  nM (Selleckchem), U0126 2  µM, LY294002 
10 µM, SB203580 2 µM (Cell Signaling Technology), 10058-F4 
40 µM, EX-527 500 nM (Tocris Bioscience), 2-Deoxy-d-Glucose 
1 mM, Etomoxir 40 µM, BAY 85-3934 1 µM, CAY-10585 10 µM 
(Cayman Chemical), nicotinic acid 10  µM (Sigma-Aldrich), 
Pyridone 6 100  nM (BioVision), Trichostatin A (TSA) 5  nM 
(Calbiochem).
elisa and nicotinamide adenine 
Dinucleotide (naD) Quantification
Cytokine concentrations in cell-free supernatants or total pro-
tein lysates (0.1% Triton X-100) were measured using ELISA 
kits for TNF-α (R&D Systems), IL-1β, and IL-6 (eBioscience). 
Standard curves were generated with a Four Parametric Logistic 
curve fit and data were analyzed using MyAssays Analysis 
Software Solutions (www.myassays.com). Cytokine levels in 
protein lysates were normalized on total protein concentrations 
as determined by Bradford protein assay (Biorad) and expressed 
as picogram of cytokine per microgram of total protein. 
Intracellular NAD levels were measured using the colorimetric 
assay NAD/NADH Quantitation assay (Sigma-Aldrich) accord-
ing to the manufacturer’s protocol and expressed as fold over 
control.
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Phospho-Flow cytometry
Monocytes were collected, rested in cIMDM-0.5 (0.5% FCS) for 
1 h, and stimulated with LPS for the indicated times. Then, cells 
were fixed with 1.5% paraformaldehyde (EM-grade, Electron 
Microscopy Sciences) and permeabilized with absolute ice-cold 
methanol. Cells were stained (60 min at room temperature) in 
PBS + 10% human AB serum (Lonza) + 0.05% NaN3 with the 
following antibodies: anti-human-phospho-p38 PE (T180/Y182) 
(3D7, dilution 1:50), anti-human-phospho-p44/42 (ERK1/2) PE 
(T202/Y204) (19762, dilution 1:50) (Cell Signaling Technology). 
Samples were acquired on MACSQuant Analyzer 10 (Miltenyi 
Biotec) and analyzed using FlowJo v10. Doublets and debris were 
excluded from the analysis. Data are expressed as percentage of 
positive cells and median fluorescence intensity (MFI).
Fluorescence, Time-lapse,  
and high-content Microscopy
Microscopy experiments were performed with the Operetta 
High-Content Imaging System (PerkinElmer). Monocytes were 
cultured in 96-well black CellCarrier plates (PerkinElmer). 
For fluorescence microscopy, cells were fixed with 1% para-
formaldehyde (EM-grade, Electron Microscopy Sciences) and 
permeabilized with PBS +  0.1% Triton X-100. Then, actin was 
stained with rhodamin phalloidin and nuclei with Hoechst 
33342 (Thermo Fisher Scientific) according to manufacturer’s 
protocol. Representative images were taken with a 60× objective. 
For time-lapse microscopy, monocytes were cultured for 6 days 
at controlled temperature (37°C) and CO2 (5%). Over this time 
window, digital phase contrast images of 15 fields/well were taken 
every 60 min with a 20× objective. Representative videos of single 
fields are shown for each experimental condition. To quantify cell 
confluency, brightfield images of 15 fields/well were taken on days 
1, 4, 7, and 8 with a 20× objective. PhenoLOGIC (PerkinElmer) 
was employed for image segmentation and to calculate the cell-
free area (b) and the area covered by cells (a). Cell confluency was 
calculated as a proportion of cell area over total cell area using the 
following formula: [a/(a + b)]  × 100.
Phagocytosis assay
Monocytes were cultured in 96-well black CellCarrier plates 
(PerkinElmer) and stimulated for 18 h without or with M-CSF, 
IL-3, and GM-CSF. Then, pHrodo Green E. coli BioParticles 
(Thermo Fisher Scientific) were added for 1 h (150 µg/mL final 
concentration) and actin and nuclei were stained as indicated 
above. Fluorescence microscopy images of 15  fields/well were 
obtained with the Operetta High-Content Imaging System 
(PerkinElmer). Cells were identified based on nuclei and actin 
staining. Then, the percentage of cells (a) that had phagocytosed 
E. coli BioParticles (i.e., cells emitting in the FITC channel) 
over total cells (b) was calculated using the following formula: 
(a/b) × 100.
rna isolation and real Time rT-Pcr
RNA was extracted using TRIzol (Thermo Fisher Scientific) 
and reverse-transcribed (500 ng) using SuperScript III Reverse 
Transcriptase (Thermo Fisher Scientific). Real-time RT-PCR was 
performed by using Universal SYBR Green Supermix (Bio-Rad) 
on CFX96 Real-time detection system (Bio-Rad). Relative quan-
tification of gene expression was calculated by the ΔCt (relative 
expression × 104) method. Each Ct value was normalized to the 
respective ubiquitin C (UBC) Ct value. The following primer 
pairs were used: TNF mRNA forward 5′-tctccttcctgatcgtggca-3′; 
TNF mRNA reverse 5′-cagcttgagggtttgctacaac-3′; TNF primary 
transcript forward 5′-taagggtgactccctcgatgt-3′; TNF primary 
transcript reverse 5′-ccaaacccaaacccagaatta-3′; SIRT2 forward 
5′-cccaaccccagcaaatctctaa-3′; SIRT2 reverse 5′-ggctggtagagatgc-
ctgtt-3′; MYC forward 5′-attctctgctctcctcgacg-3′; MYC reverse 
5′-agcctgcctcttttccaca-3′; MAFB forward 5′-gtatgaaccgcatggt-
gcttg-3′; MAFB reverse 5′-ctgttgcggcaggtttgatt-3′; UBC forward 
5′-ggtcgcagttcttgtttg-3′; UBC reverse 5′-gatggtcttaccagtcaga-3′.
statistical analysis
Statistical analysis was performed with Prism 6 (GraphPad 
Software). P values were calculated as indicated in figure legends. 
P < 0.05 was considered significant.
resUlTs
gM-csF and il-3 Priming enhances  
lPs-induced TnF-α Production
In order to evaluate the effect of GM-CSF and IL-3 on the 
pro-inflammatory LPS-mediated activation of human CD14+ 
monocytes, we simultaneously treated these cells with LPS and 
GM-CSF or IL-3 and then assessed the production of TNF-α, 
IL-1β, and IL-6. To our surprise, neither GM-CSF (Figure S1A in 
Supplementary Material) nor IL-3 (Figure S1B in Supplementary 
Material) modulated cytokine production in response to LPS. 
Since several stimuli may act as priming stimuli (18, 19), we 
reasoned that GM-CSF and IL-3 could prime monocytes for 
increased responsiveness to LPS. Monocytes were left untreated 
(CTRL) or treated for 18  h with M-CSF, IL-3, or GM-CSF, 
washed and then stimulated with LPS for additional 16–18  h 
(short-term model of trained immunity). Interestingly, priming 
with GM-CSF or IL-3 increased LPS-induced TNF-α produc-
tion, while IL-1β and IL-6 were marginally affected (Figure 1) 
and no IL-12p70 production was detected (data not shown). 
Furthermore, GM-CSF and IL-3 priming did not enhance E. 
coli phagocytosis (Figure S2 in Supplementary Material). To 
verify whether the priming effect was shared among differ-
ent TLRs, we stimulated primed monocytes with LPS (TLR4 
agonist), P3CSK4 (TLR2 agonist), Poly(I:C) (TLR3 agonist), 
flagellin (TLR5 agonist), imiquimod (TLR7 agonist), or ODN 
2006 (TLR9 agonist). The priming effect was more pronounced 
when monocytes were stimulated with LPS, although a trend 
toward an increase in TNF-α production was also observed with 
P3CSK4 (Figure S3 in Supplementary Material). Finally, a time-
course analysis revealed that at least 3 h (for IL-3) or 6 h (for 
GM-CSF) of priming were required to observe increased TNF-α 
secretion upon LPS stimulation (Figure S4 in Supplementary 
Material).
To gain insights into the molecular mechanisms of monocyte 
priming, we selectively treated monocytes during the priming 
FigUre 2 | gM-csF and il-3 priming modulates TnF-α protein abundance at the posttranscriptional level. (a–F) Human CD14+ monocytes were primed 
with GM-CSF and IL-3 for 18 h (day 1), then washed, and stimulated with LPS (day 2) for 1 h (a,c,e) or 4 h (B,D,F). TNF-α protein abundance (a,B) was measured 
in protein lysates by ELISA. TNF primary transcript (c,D) and mRNA (e,F) were measured by real-time RT-PCR. Data are shown as the median, the 25th and 75th 
percentiles (boxes) and 5th and 95th percentiles (whiskers) of eight independent experiments. *P < 0.05, **P < 0.01 determined by Friedman test with Dunn’s 
post hoc test.
FigUre 1 | gM-csF and il-3 priming enhances TnF-α production upon lPs stimulation in a short-term model of trained immunity. Human CD14+ 
monocytes were left unprimed (CTRL) or primed with M-CSF, IL-3, and GM-CSF for 18 h (day 1), then washed, and left untreated or stimulated with LPS for 
16–18 h (day 2). TNF-α, IL-1β, and IL-6 levels were assessed by ELISA in cell-free supernatants. Data are shown as mean + SEM of seven independent 
experiments. **P < 0.01 determined by repeated measure two-way ANOVA with Sidak’s post hoc test.
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phase with inhibitors of pathways that are known to modulate 
monocyte and macrophage activation: JAK2 (TG101348), 
NF-κB (BAY 11-7082), c-Myc (10058 F4), HIF-1α (CAY10585), 
PHD (BAY 85-3934), PI3K (LY294002), MEK1/2 (U0126), p38 
(SB203580), JNK (SP600125), hexokinase (2-Deoxy-d-Glucose, 
inhibitor of glycolysis), CPT1 (etomoxir, inhibitor of fatty acid 
β-oxidation). The readout of these experiments was the modula-
tion of TNF-α production by primed monocytes without affecting 
unprimed cells. Most of the inhibitors had no or negligible effects 
on primed cells, while TG101348 reduced TNF-α production by 
both primed and unprimed cells (Figure S5 in Supplementary 
Material).
gM-csF and il-3 Priming Modulates 
TnF-α Production at the 
Posttranscriptional level
To obtain some clue on the modulation of TNF-α in GM-CSF and 
IL-3 primed monocytes, we performed a time-course analysis of 
TNF-α intracellular protein, primary transcript (which is a more 
direct measure of transcription and is detected by using intronic 
PCR primers) (24), and mRNA levels. GM-CSF and IL-3 prim-
ing resulted in the highest TNF-α intracellular protein levels as 
early as after 1 h of LPS stimulation (Figure 2A). After 4 h of LPS 
stimulation, TNF-α intracellular protein levels were even more 
FigUre 3 | gM-csF and il-3 priming increases p38 and erK1/2 phosphorylation upon lPs stimulation. (a,B) Human CD14+ monocytes were left 
unprimed (CTRL) or primed with M-CSF, IL-3, and GM-CSF for 18 h (day 1), then washed, and left untreated (0 min) or stimulated with LPS for different time points 
(15, 30, and 60 min). (a) p38 phosphorylation was assessed by flow cytometry as percentage (left panel) and median fluorescence intensity (MFI) (right panel) of 
pp38+ cells. (B) ERK1/2 phosphorylation was assessed by flow cytometry as MFI. (c) Representative histograms of p38 and ERK1/2 phosphorylation. Data are 
shown as mean + SEM of eight independent experiments. *P < 0.05, **P < 0.01 determined by repeated measure two-way ANOVA with Tukey’s post hoc test.
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increased in primed monocytes (Figure 2B). The same pattern of 
TNF-α production was observed in cell-free supernatants (data 
not shown). Unexpectedly, TNF primary transcript (Figure 2C) 
and mRNA (Figure 2E) levels were either not modified or only 
slightly increased by GM-CSF and IL-3 priming after 1  h of 
LPS stimulation. After 4 h, IL-3 priming increased TNF mRNA 
levels (Figure  2F) whereas TNF primary transcript levels were 
unchanged compared to unprimed cells (Figure 2D), suggesting 
that IL-3 priming increases TNF mRNA stability. Thus, GM-CSF 
and IL-3 priming uncouples TNF-α protein and primary 
transcript levels upon LPS stimulation, thereby suggesting that 
TNF-α expression is modulated at the posttranscriptional level 
in primed monocytes.
naD-Dependent sirT2 and MaPKs 
erK1/2 and p38 Mediate the effect of 
gM-csF and il-3 Priming on TnF-α 
Production
The expression of several genes with immune function 
(including TNF-α) can be regulated at the translational level, 
thereby modulating protein abundance independently of 
FigUre 4 | gM-csF and il-3 priming requires the nicotinamide adenine dinucleotide-dependent histone deacetylase sirT2. (a–D) Human CD14+ 
monocytes were primed with GM-CSF and IL-3 for 18 h in the presence of several compounds (day 1), then washed, and stimulated with LPS for 16–18 h (day 2). 
TNF-α levels were assessed by ELISA in cell-free supernatants. Data are shown as mean + SEM of seven independent experiments. **P < 0.01 determined by 
repeated measure two-way ANOVA with Tukey’s (a) or Sidak’s (B–D) post hoc test.
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de novo transcription (33–35). A central (albeit not exclusive) 
role in the modulation of mRNA translation is played by the 
translation-initiation factor eIF4E, whose activity is regulated 
by mTORC1 (a multiprotein complex that includes the serine/
threonine kinase mTOR and raptor) and the MAPKs ERK1/2 
and p38 (34). TNF-α protein levels are also regulated by meta-
bolic cues. Depletion of the intracellular pool of nicotinamide 
adenine dinucleotide (NAD) by the nicotinamide phospho-
ribosyltransferase (Nampt) inhibitor APO866 inhibits TNF-α 
protein production in response to LPS without modifying TNF 
mRNA levels. The effect of APO866 is reverted by the addition 
of nicotinic acid [(NA), a substrate for Nampt-independent 
NAD synthesis] and is mimicked by inhibitors of the NAD-
dependent histone deacetylases sirtuin (SIRT) 1 and 2 (36, 
37). Thus, we reasoned that these pathways could contribute 
to the modulation of TNF-α protein levels in GM-CSF 
and IL-3-primed cells and proceeded to investigate this 
hypothesis.
First, we assessed the contribution of mTORC1 by employing 
two different mTOR inhibitors (rapamycin and torin 1) and also 
an inhibitor of SIRT2 (which is involved in the regulation of 
the mTOR-activated translational machinery) (38). We added 
the inhibitors along with LPS and evaluated TNF-α intracellular 
protein levels after 1 h of stimulations. None of these inhibitors 
modulated TNF-α production in both unprimed and primed 
monocytes (Figure S6 in Supplementary Material). Then, we 
employed the same approach using inhibitors of MAPKs (i.e., 
ERK1/2, p38, and JNK). The p38 inhibitor SB203580 reduced 
TNF-α intracellular protein in both unprimed and GM-CSF or 
IL-3 primed cells (Figure S7A in Supplementary Material), while 
ERK1/2 inhibition with the MEK1/2 inhibitor U0126 was effec-
tive only in GM-CSF primed cells (Figure S7B in Supplementary 
Material). No effect for the JNK inhibitor SP600125 could be 
observed (data not shown). Importantly, ERK1/2 (Figures S7D,F 
in Supplementary Material) and p38 inhibition (Figures S7C,E 
in Supplementary Material) did not significantly modulate TNF 
RNA levels. To corroborate these findings, we performed a time-
course analysis of p38 and ERK1/2 phosphorylation (pp38 and 
pERK1/2, respectively) upon LPS stimulation. As early as after 
15 min of stimulation, GM-CSF and IL-3-primed cells exhibited 
the highest phosphorylation of p38, as assessed by the percent-
age (compared to unprimed cells) and the MFI (compared to 
M-CSF primed cells) of pp38+ cells (Figure 3A). On the con-
trary, only GM-CSF-primed cells exhibited increased ERK1/2 
phosphorylation compared to unprimed or M-CSF-primed cells 
(Figures 3B,C).
Then, we used APO866 and NA to evaluate whether intracel-
lular NAD levels contributed to the priming effect of GM-CSF 
and IL-3. APO866 concentration-dependently inhibited TNF-α 
secretion only when administered during priming (Figure S8A 
in Supplementary Material). Importantly, the addition of NA 
reverted the effect of APO866 (Figure  4A). We verified that 
APO866 reduced while NA addition restored intracellular NAD 
levels (Figure S8B in Supplementary Material). Interestingly, 
GM-CSF and IL-3 priming increased intracellular NAD levels 
compared to unprimed cells. However, the same effect was 
observed with M-CSF priming (Figure S8C in Supplementary 
Material), which does not modulate TNF-α secretion. We also 
confirmed that unprimed and M-CSF, IL-3, and GM-CSF-
primed monocytes expressed comparable levels of SIRT2 
mRNA (Figure S8D in Supplementary Material). Thus, the 
increase in intracellular NAD levels is a condition required but 
not sufficient for the priming effect of GM-CSF and IL-3. We 
then evaluated the involvement of the NAD-dependent histone 
deacetylases SIRT1 and SIRT2 in GM-CSF and IL-3 priming by 
using the specific inhibitors EX-527 and AGK2, respectively. 
SIRT2 inhibition during priming selectively reduced TNF-α 
secretion (Figures 4C,D) and intracellular protein levels (Figure 
S9A in Supplementary Material) without significantly modulat-
ing TNF RNA (Figures S9B,C in Supplementary Material), 
FigUre 5 | gM-csF and il-3 priming induces monocyte renewal in a long-term model of trained immunity. (a) Schematic representation of the 
long-term model of trained immunity. (B–D) Human CD14+ monocytes were treated as outlined above (a). On day 7, cells were stimulated with LPS for 16–18 h 
(B,c) or 1 h (D). TNF-α levels were assessed by ELISA in cell-free supernatants (B). Cells were harvested for total protein quantification (c) or RNA extraction and 
evaluation of TNF primary transcript and mRNA levels by real time RT-PCR (D). (e–g) Human CD14+ monocytes were treated as outlined above (a) and on day 7 
were stimulated with LPS for 16–18 h. Brightfield images (15 fields/well) were obtained at the indicated time points with a 20× objective. The percentage of cell area/
total area was calculated and expressed as absolute values (e) or fold increase over day 1 (F). On day 8, representative fluorescence microscopy images were also 
obtained with a 60× objective. Orange, actin; blue, nuclei (g). Data are shown as mean + SEM of 10 (B,c), five (D), or eight (e,F) independent experiments. 
*P < 0.05, **P < 0.01 determined by repeated measure one-way (B–D) or two-way (e,F) ANOVA with Tukey’s post hoc test.
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although the effect was more pronounced for IL-3 rather than 
GM-CSF- primed cells. We confirmed the specificity of SIRT2 
involvement by showing that the inhibitor of NAD-independent 
histone deacetylases TSA had no effect on GM-CSF and IL-3 
priming (Figure 4B).
gM-csF and il-3 Priming Modulates 
Monocyte renewal in a c-Myc-Dependent 
Manner
The results obtained so far have characterized the role of GM-CSF 
and IL-3 in a short-term model of trained immunity. Since the 
FigUre 6 | gM-csF and il-3 elicited monocyte renewal requires c-Myc. (a) Human CD14+ monocytes were primed with IL-3, M-CSF, or GM-CSF for 18 h. 
Then, cells were harvested for RNA isolation and MYC and MAFB mRNA levels were evaluated by real-time RT-PCR. (B) Human CD14+ monocytes were treated as 
outlined in Figure 5a using GM-CSF, IL-3, and M-CSF as priming stimuli. Cells were also treated with the c-Myc inhibitor 10058 F4 on day 1 (left panels), day 1 and 
2 (middle panels), day 1, 2, and 4 (right panels). Analysis was performed as in Figure 5F. Data are shown as mean + SEM of seven (a) or eight (B) independent 
experiments. *P < 0.05, **P < 0.01 determined by repeated measure one-way (a) or two-way (B) ANOVA with Tukey’s post hoc test.
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effects of training can be retained by human monocytes for several 
days even in the absence of the training stimulus (e.g., β-glucan) 
(26, 29), we investigated the possible roles of GM-CSF and IL-3 in 
a long-term model of trained immunity. Monocytes were primed 
with GM-CSF, IL-3, M-CSF, and LPS for 16–18 h, washed out, and 
rested in complete medium until day 7 when they were stimulated 
with LPS (Figure 5A). In accordance with the results obtained 
with β-glucan, cells primed with GM-CSF or IL-3 secreted 
higher levels of TNF-α compared to those primed with M-CSF 
and LPS (Figure 5B). Although these results could suggest stable 
chromatin remodeling events in response to GM-CSF and IL-3 
priming (similar to what has been demonstrated for β-glucan), 
we also found that GM-CSF and IL-3 priming increased total 
cellular protein content (Figure 5C) and that monocytes primed 
with GM-CSF, IL-3, and M-CSF expressed comparable levels of 
TNF RNA upon LPS stimulation (Figure 5D). Thus, we reasoned 
that GM-CSF and IL-3 priming could induce monocyte renewal 
and increase the number of cells, which in turn would result in 
higher TNF-α secretion upon LPS stimulation. We investigated 
this hypothesis by evaluating the degree of cell confluency 
(assessed as the proportion of cell area to total area). Monocytes 
primed with GM-CSF and IL-3 reached remarkable higher cell 
confluency on day 7 compared to monocyte primed with M-CSF 
or LPS (Figure  5E). Comparable results were obtained when 
we expressed cell confluency on days 4, 7, and 8 as fold increase 
over day 1 to account for possible differences in cell detachment 
after the washing step (Figure  5F). We also obtained evidence 
of increased cell number following GM-CSF and IL-3 priming 
by fluorescence (Figure 5G) and time-lapse microscopy (Videos 
S1–S4 in Supplementary Material). Thus, GM-CSF and IL-3 
priming induces monocyte renewal in a long-term model of 
trained immunity.
Maintenance of the pool of tissue-resident macrophages is sup-
ported by self-renewal without the contribution of hematopoietic 
stem cell in several experimental models (39–51). Interestingly, 
macrophage renewal is sustained by a gene network that includes 
the transcription factor c-Myc and requires downregulation of the 
transcription factor MafB (49, 52, 53). In keeping with these data, 
GM-CSF and IL-3 priming increased the MYC/MAFB mRNA 
ratio compared to M-CSF priming (Figure 6A). Moreover, the 
c-Myc inhibitor 10058 F4 restrained monocyte renewal induced 
by GM-CSF and IL-3 priming (Figure 6B). To better characterize 
FigUre 7 | gM-csF and il-3 priming induces monocyte renewal through different signaling pathways. (a–F) Human CD14+ monocytes were treated as 
outlined in Figure 5a using GM-CSF and IL-3 as priming stimuli. Cells were also treated with different inhibitors during the priming phase. Analysis was performed 
as in Figure 5F. Data are shown as mean + SEM of eight independent experiments. *P < 0.05, **P < 0.01 determined by repeated measure two-way ANOVA with 
Tukey’s post hoc test.
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the pathways required for GM-CSF- and IL-3-induced monocyte 
renewal, several inhibitors were added along with GM-CSF or 
IL-3 and then cell confluency was evaluated as indicated above. 
Metabolic inhibitors (2-Deoxy-d-Glucose, etomoxir, APO866) 
(Figure S10 in Supplementary Material) as well as the JNK inhibi-
tor SP600125 (Figure 7F) had no effect on cell confluency. The 
selective JAK2 inhibitor TG101348 (Figure  7A), the pan-JAK 
inhibitor Pyridone 6 (Figure 7B), and the p38 inhibitor SB203580 
(Figure  7C) restrained only IL-3 priming-induced monocyte 
expansion. Finally, the PI3K inhibitor LY294002 (Figure  7D) 
and the MEK1/2 inhibitor U0126 (which in turn inhibits ERK1/2 
activity) (Figure 7E) reduced monocyte expansion in response 
to both GM-CSF and IL-3 priming, although IL-3 priming was 
affected to a greater degree.
DiscUssiOn
Here, we show that GM-CSF and IL-3, hematopoietic cytokines 
that play a central role in regulating myeloid cell expansion and 
effector response in several in vivo models of inflammation and 
autoimmunity, modulate human CD14+ monocyte response in 
short- and long-term models of trained immunity. To understand 
the regulation of TNF-α production in primed monocytes, we 
compared intracellular TNF-α protein levels, TNF mRNA, and 
primary transcript levels upon LPS stimulation for 1 and 4  h. 
Although in several experimental models priming of monocyte 
and macrophages results in chromatin remodeling (20, 22–24, 
26–30), our data support a posttranscriptional regulation of 
TNF-α production in primed monocytes. Posttranscriptional 
mechanisms, including modulation of mRNA stability and 
translation (33–35), are increasingly recognized as critical 
regulators of gene and protein expression also in immune cells 
(25, 34, 36, 37, 54, 55). Our results demonstrate that inhibition 
of SIRT2 during priming and of p38 or ERK1/2 (the latter only 
for GM-CSF primed cells) during LPS stimulation reduces intra-
cellular TNF-α protein levels without significantly modulating 
TNF RNA levels. In keeping with these data, GM-CSF priming 
increases phosphorylation of both ERK1/2 and p38 upon LPS 
stimulation, while IL-3 priming enhances only p38 phosphoryla-
tion. However, it is still unclear how SIRT2 inhibition during the 
priming phase modulates TNF-α protein production. We verified 
that SIRT2 inhibition during the priming phase does not reduce 
ERK1/2 and p38 phosphorylation upon LPS stimulation (Figures 
S11A,B in Supplementary Material). Nevertheless, the phenotype 
of GM-CSF- and IL-3-primed monocytes may be regulated by 
pathways not investigated in this study. Apart from the molecular 
mechanisms that may also reveal subtle differences in monocyte 
responsiveness to GM-CSF and IL-3 priming, genome-wide 
approaches aimed at evaluating the translatome or at comparing 
the transcriptome and the proteome may provide critical insights 
into the modulation of LPS-induced monocyte response by 
GM-CSF and IL-3 priming.
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In order to fully characterize the priming effect of GM-CSF 
and IL-3, we also employed a long-term model of trained 
immunity. Using this model, it was shown that human monocyte 
primed with β-glucan undergo extensive chromatin remodeling 
that modulate their response to subsequent microbial challenges 
(e.g., increased TNF-α production upon LPS stimulation) (26, 
29). Our results demonstrate that GM-CSF and IL-3 priming 
increases LPS-induced TNF-α production in this model, but the 
mechanism is independent of increased TNF gene expression 
(and likely chromatin remodeling). Instead, GM-CSF and IL-3 
priming induces monocyte renewal by increasing the MYC/MAFB 
mRNA ratio. Interestingly, proliferation of monocyte-derived 
cells (either macrophages or dendritic cells) has been observed 
in several models of inflammation (49, 56, 57). Although we 
found similarities as well as differences between GM-CSF and 
IL-3 priming in the pathways required for monocyte renewal, it 
is noteworthy that GM-CSF priming induces a greater monocyte 
expansion than IL-3 priming. The reason for this difference prob-
ably relies in the constitutive expression of CD116 (the α subunit 
of GM-CSF receptor) by human monocytes (58), while CD123 
(the α subunit of IL-3 receptor) expression is inducible (16, 59). 
Nevertheless, bone marrow CD14+ monocytes express CD123 
(60), thus it is tempting to speculate that IL-3 preferentially acts 
on bone marrow-resident monocytes, while GM-CSF exerts its 
effect on peripheral blood monocytes. Moreover, since priming 
with both cytokines induces monocyte renewal and priming also 
affects the biology of hematopoietic precursors (61–63), it would 
be interesting to assess whether GM-CSF and IL-3 priming can 
modulate the functions of hematopoietic precursors and their 
progeny. Further studies are required to address these questions.
In conclusion, we characterize the activation of human 
monocytes in response to the hematopoietic cytokines GM-CSF 
and IL-3 using in vitro models of trained immunity. Our results 
point to mechanisms of GM-CSF and IL-3 priming that are 
independent of chromatin remodeling, but unexpectedly rely on 
posttranscriptional regulation of TNF-α production and c-Myc-
dependent monocyte renewal. Given the central role of GM-CSF 
and IL-3 in inflammatory and autoimmune diseases (6–11), our 
results provide important information to understand mecha-
nisms of monocyte activation in such disorders and prompt their 
investigation in vivo. We also demonstrate that GM-CSF and IL-3 
activate monocytes through shared as well as distinct pathways. 
Such differences may become even more evident in vivo, since 
it is conceivable that GM-CSF and IL-3 are produced with a 
different timing and/or act on different target populations (e.g., 
bone marrow vs. peripheral cells). Thus, GM-CSF and IL-3 may 
differentially impact on the immune response due to distinct 
effects at the cellular and the system levels. Understanding such 
complexity is poised to unravel distinct as well as overlapping 
roles for GM-CSF and IL-3 in health and disease.
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